Tracy Gasperetti

Tracy Gasperetti

Auto-generated profile, based on publicly available information

Tracy Gasperetti

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Guru Prasad Sharma,Guru Prasad Sharma,
Guru Prasad Sharma,
AFAnne C. Frei
Anne C. Frei
JNJayashree Narayanan
Jayashree Narayanan
TGTracy Gasperetti
Tracy Gasperetti
DVDana Veley
Dana Veley
HHHeather Anne Himburg
Heather Anne Himburg
Brain-derived neurotrophic factor (BDNF) is a member of the nerve growth factor family which has been extensively studied for its roles in neural development, long-term memory, brain injury, and neurodegenerative diseases. BDNF signaling through tropomyosin receptor kinase B (TrkB) stimulates neuronal cell survival. For this reason, small molecule TrkB agonists are under pre-clinical develoment for the treatment of a range of neurodegenerative diseases and injuries. Our laboratory recently reported BDNF is secreted by pro-regenerative endothelial progenitor cells (EPCs) which support hematopoietic reconstitution following total body irradiation (TBI). Here we report BDNF-TrkB signaling plays a novel regenerative role in bone marrow and thymic regeneration following radiation injury. Exogenous administration of BDNF or TrkB agonist 7,8-dihydroxyflavone (7,8-DHF) following myelosuppressive radiation injury promoted faster recovery of mature blood cells and hematopoietic stem cells capable of multi-lineage reconstitution. BDNF promotes hematopoietic regeneration via activation of PDGFRα+bone marrow mesenchymal stem cells (MSCs) which increase secretion of hematopoietic cytokines interleukin 6 (IL-6) and leukemia inhibitory factor (LIF) in response to TrkB activation. These data suggest pharmacologic activation of the BDNF pathway with either BDNF or 7,8-DHF may be beneficial for treatment of radiation or chemotherapy induced myelosuppression.

12 November 2024 in International Journal of Radiation Biology
Verified
Journal Article
Open access
RWRadoslaw Wesolowski
Radoslaw Wesolowski
BFBrian L. Fish
Brian L. Fish
MEMichael Eibl
Michael Eibl
SBStella Bähr
Stella Bähr
SMSrishti Munjal Mehta
Srishti Munjal Mehta
DPDirk Pleimes
Dirk Pleimes
Repurposing therapeutic agents with existing clinical data is a common strategy for developing radiation countermeasures. IEPA (imidazolyl ethanamide pentandioic acid) is an orally bioavailable small molecule pseudopeptide with myeloprotective properties, a good clinical safety profile, and stable chemical characteristics facilitating stockpiling. Here, we evaluated IEPA's radiomitigative efficacy in the hematopoietic subsyndrome of acute radiation syndrome (H-ARS) using total-body irradiation (TBI) models in C57BL/6J mice and WAG/RijCmcr rats, applying various posology schemes and introducing syringe feeding of the IEPA formulation in the pudding. Additionally, we assessed IEPA in the delayed effects of acute radiation exposure (DEARE) model after partial-body irradiation (PBI) in WAG/RijCmcr rats. Endpoints included survival, body weight, hematology, and pulmonary parameters, depending on the model. Results from mouse and rat TBI models demonstrated survival improvements with repeated IEPA dosing at 10 mg/kg, with the largest benefits observed in the bi-daily (BID) treatment over the 30-day ARS phase in female rats. Survival across PBI-DEARE subsyndromes was comparable between IEPA and vehicle groups, though IEPA improved pulmonary parameters in female rats during the lung-DEARE phase. Sex-related differences in response to irradiation and IEPA were noted, with females showing a survival advantage. IEPA treatment is compatible with Neulasta® (Pegfilgrastim; PEG-G-CSF); adequately powered studies are needed to confirm the trend toward improved survival over standard care alone. IEPA is a promising development candidate as a medical countermeasure against the effects of acute radiation syndrome. Further confirmatory studies in small and large animal models should validate the robustness and translatability of preliminary rodent data on IEPA's radiomitigative efficacy.

18 November 2026 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
MEMichael Eibl
Michael Eibl
NSNikita Singh
Nikita Singh
Guru Prasad Sharma,Guru Prasad Sharma,
Guru Prasad Sharma,
NKNaomi Kast
Naomi Kast
SGStephanie Gurka
Stephanie Gurka
RWRadoslaw Wesolowski
Radoslaw Wesolowski